These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 30617648)

  • 1. Predictive value of MLH1 and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer.
    Hashimoto T; Kurokawa Y; Takahashi T; Miyazaki Y; Tanaka K; Makino T; Yamasaki M; Nakajima K; Ikeda JI; Mori M; Doki Y
    Gastric Cancer; 2019 Jul; 22(4):785-792. PubMed ID: 30617648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
    Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
    Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.
    Sloan EA; Ring KL; Willis BC; Modesitt SC; Mills AM
    Am J Surg Pathol; 2017 Mar; 41(3):326-333. PubMed ID: 27984238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression Profile of Markers for Targeted Therapy in Gastric Cancer Patients: HER-2, Microsatellite Instability and PD-L1.
    Pereira MA; Ramos MFKP; Dias AR; Faraj SF; Ribeiro RRE; de Castria TB; Zilberstein B; Alves VAF; Ribeiro U; de Mello ES
    Mol Diagn Ther; 2019 Dec; 23(6):761-771. PubMed ID: 31595457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diffuse Intratumoral Stromal Inflammation in Ovarian Clear Cell Carcinoma is Associated With Loss of Mismatch Repair Protein and High PD-L1 Expression.
    Lin SY; Hang JF; Lin YY; Lai CR; Ho HL; Chou TY
    Int J Gynecol Pathol; 2021 Mar; 40(2):148-155. PubMed ID: 32897958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunochemotherapy benefits in gastric cancer patients stratified by programmed death-1 ligand-1.
    Hsu JT; Hsu CS; Le PH; Chen TC; Chou WC; Lin CY; Yeh TS
    J Surg Res; 2017 May; 211():30-38. PubMed ID: 28501128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microsatellite Instability and Programmed Cell Death-Ligand 1 Expression in Stage II/III Gastric Cancer: Post Hoc Analysis of the CLASSIC Randomized Controlled study.
    Choi YY; Kim H; Shin SJ; Kim HY; Lee J; Yang HK; Kim WH; Kim YW; Kook MC; Park YK; Kim HH; Lee HS; Lee KH; Gu MJ; Choi SH; Hong S; Kim JW; Hyung WJ; Noh SH; Cheong JH
    Ann Surg; 2019 Aug; 270(2):309-316. PubMed ID: 29727332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Programmed Cell Death Ligand (PD-L1) Expression in Stage II and III Lung Adenocarcinomas and Nodal Metastases.
    Uruga H; Bozkurtlar E; Huynh TG; Muzikansky A; Goto Y; Gomez-Caraballo M; Hata AN; Gainor JF; Mark EJ; Engelman JA; Lanuti MD; Mino-Kenudson M
    J Thorac Oncol; 2017 Mar; 12(3):458-466. PubMed ID: 27815126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic and Predictive Value of Microsatellite Instability, Inflammatory Reaction and PD-L1 in Gastric Cancer Patients Treated with Either Adjuvant 5-FU/LV or Sequential FOLFIRI Followed by Cisplatin and Docetaxel: A Translational Analysis from the ITACA-S Trial.
    Di Bartolomeo M; Morano F; Raimondi A; Miceli R; Corallo S; Tamborini E; Perrone F; Antista M; Niger M; Pellegrinelli A; Randon G; Pagani F; Martinetti A; Fucà G; Pietrantonio F;
    Oncologist; 2020 Mar; 25(3):e460-e468. PubMed ID: 32162808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcomes and biomarker exploration of first-line PD-1 inhibitors plus chemotherapy in patients with low PD-L1-expressing of gastric or gastroesophageal junction adenocarcinoma.
    Sun YT; Lu SX; Lai MY; Yang X; Guan WL; Yang LQ; Li YH; Wang FH; Yang DJ; Qiu MZ
    Cancer Immunol Immunother; 2024 Jun; 73(8):144. PubMed ID: 38832979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological and prognostic features of Epstein-Barr virus infection, microsatellite instability, and PD-L1 expression in gastric cancer.
    Pereira MA; Ramos MFKP; Faraj SF; Dias AR; Yagi OK; Zilberstein B; Cecconello I; Alves VAF; de Mello ES; Ribeiro U
    J Surg Oncol; 2018 Apr; 117(5):829-839. PubMed ID: 29534305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of PD-L1 expression is associated with EMAST, density of peritumoral T-cells and recurrence-free survival in operable non-metastatic colorectal cancer.
    Watson MM; Lea D; Gudlaugsson E; Skaland I; Hagland HR; Søreide K
    Cancer Immunol Immunother; 2020 Aug; 69(8):1627-1637. PubMed ID: 32314040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The PD-1, PD-L1 expression and CD3+ T cell infiltration in relation to outcome in advanced gastric signet-ring cell carcinoma, representing a potential biomarker for immunotherapy.
    Jin S; Xu B; Yu L; Fu Y; Wu H; Fan X; Wei J; Liu B
    Oncotarget; 2017 Jun; 8(24):38850-38862. PubMed ID: 28418918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Expression level and prognostic value of PD-L1 in microsatellite instability-high gastric cancer].
    Wang XY; Hu YJ; Dong K; Zhao C; Huang XZ; Lian SY; Sun Y
    Zhonghua Bing Li Xue Za Zhi; 2020 Nov; 49(11):1114-1119. PubMed ID: 33152814
    [No Abstract]   [Full Text] [Related]  

  • 15. Microsatellite instability (MSI-H) is associated with a high immunoscore but not with PD-L1 expression or increased survival in patients (pts.) with metastatic colorectal cancer (mCRC) treated with oxaliplatin (ox) and fluoropyrimidine (FP) with and without bevacizumab (bev): a pooled analysis of the AIO KRK 0207 and RO91 trials.
    Noepel-Duennebacke S; Juette H; Schulmann K; Graeven U; Porschen R; Stoehlmacher J; Hegewisch-Becker S; Raulf A; Arnold D; Reinacher-Schick A; Tannapfel A
    J Cancer Res Clin Oncol; 2021 Oct; 147(10):3063-3072. PubMed ID: 33675399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. β-catenin and PD-L1 expression in mismatch repair deficient endometrial carcinomas.
    Rowe M; Krishnan R; Mills A; Ring K
    Int J Gynecol Cancer; 2020 Jul; 30(7):993-999. PubMed ID: 32376735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-L1 Acts as a Promising Immune Marker to Predict the Response to Neoadjuvant Chemotherapy in Breast Cancer Patients.
    Du Q; Che J; Jiang X; Li L; Luo X; Li Q
    Clin Breast Cancer; 2020 Feb; 20(1):e99-e111. PubMed ID: 31521537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spatial and Temporal Heterogeneity of PD-L1 Expression and Tumor Mutational Burden in Gastroesophageal Adenocarcinoma at Baseline Diagnosis and after Chemotherapy.
    Zhou KI; Peterson B; Serritella A; Thomas J; Reizine N; Moya S; Tan C; Wang Y; Catenacci DVT
    Clin Cancer Res; 2020 Dec; 26(24):6453-6463. PubMed ID: 32820017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discordancy and changes in the pattern of programmed death ligand 1 expression before and after platinum-based chemotherapy in metastatic gastric cancer.
    Yang JH; Kim H; Roh SY; Lee MA; Park JM; Lee HH; Park CH; Lee HH; Jung ES; Lee SH; Lee YJ; Choi MH; Kim O; Kim IH
    Gastric Cancer; 2019 Jan; 22(1):147-154. PubMed ID: 29860599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic impact of PD-L1 expression in primary gastric and intestinal diffuse large B-cell lymphoma.
    Ishikawa E; Nakamura M; Shimada K; Tanaka T; Satou A; Kohno K; Sakakibara A; Furukawa K; Yamamura T; Miyahara R; Nakamura S; Kato S; Fujishiro M
    J Gastroenterol; 2020 Jan; 55(1):39-50. PubMed ID: 31493237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.